Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells

Crohn's disease (CD) is an inflammatory disorder of the intestines characterized by epithelial barrier dysfunction and mucosal damage. The activity of poly(ADP-ribose) polymerase-1 (PARP-1) is deeply involved in the pathomechanism of inflammation since it leads to energy depletion and mitochond...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovács, Dominika, Vántus, Viola Bagóné, Vámos, Eszter, Kálmán, Nikoletta, Schicho, Rudolf, Gallyas, Ferenc, Radnai, Balázs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457969/
https://www.ncbi.nlm.nih.gov/pubmed/34567413
http://dx.doi.org/10.1155/2021/7308897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457969/
https://www.ncbi.nlm.nih.gov/pubmed/34567413
http://dx.doi.org/10.1155/2021/7308897

Ejemplares similares